Aberdeen Group’s CVS Health CVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $180M | Buy |
1,739,609
+125,103
| +8% | +$11.2M | 0.25% | 65 |
|
|
2026
Q1 | $116M | Sell |
1,614,506
-30,523
| -2% | -$2.35M | 0.19% | 102 |
|
|
2025
Q4 | $131M | Sell |
1,645,029
-46,103
| -3% | -$3.63M | 0.2% | 95 |
|
|
2025
Q3 | $128M | Buy |
1,691,132
+512,844
| +44% | +$35.1M | 0.2% | 97 |
|
|
2025
Q2 | $81.3M | Buy |
1,178,288
+34,810
| +3% | +$2.28M | 0.14% | 138 |
|
|
2025
Q1 | $77.3M | Buy |
1,143,478
+393,367
| +52% | +$23.5M | 0.15% | 130 |
|
|
2024
Q4 | $33.2M | Sell |
750,111
-53,815
| -7% | -$3.02M | 0.06% | 277 |
|
|
2024
Q3 | $50.2M | Sell |
803,926
-629,674
| -44% | -$36.7M | 0.09% | 219 |
|
|
2024
Q2 | $84.7M | Sell |
1,433,600
-179,748
| -11% | -$11.2M | 0.16% | 136 |
|
|
2024
Q1 | $129M | Sell |
1,613,348
-334,480
| -17% | -$25.5M | 0.25% | 93 |
|
|
2023
Q4 | $154M | Sell |
1,947,828
-1,032,565
| -35% | -$73.5M | 0.33% | 62 |
|
|
2023
Q3 | $208M | Sell |
2,980,393
-78,230
| -3% | -$5.54M | 0.53% | 42 |
|
|
2023
Q2 | $211M | Buy |
3,058,623
+50,882
| +2% | +$3.62M | 0.49% | 46 |
|
|
2023
Q1 | $224M | Buy |
3,007,741
+2,922
| +0.1% | +$245K | 0.56% | 37 |
|
|
2022
Q4 | $280M | Buy |
3,004,819
+29,071
| +1% | +$2.81M | 0.76% | 23 |
|
|
2022
Q3 | $284M | Buy |
2,975,748
+2,074,600
| +230% | +$205M | 0.84% | 18 |
|
|
2022
Q2 | $83.7M | Buy |
901,148
+316,338
| +54% | +$30.9M | 0.26% | 86 |
|
|
2022
Q1 | $59.9M | Sell |
584,810
-147,750
| -20% | -$15.5M | 0.15% | 143 |
|
|
2021
Q4 | $75.6M | Sell |
732,560
-296,057
| -29% | -$27.4M | 0.17% | 134 |
|
|
2021
Q3 | $88.2M | Sell |
1,028,617
-233,210
| -18% | -$19.5M | 0.2% | 115 |
|
|
2021
Q2 | $105M | Buy |
1,261,827
+379,203
| +43% | +$31.1M | 0.23% | 94 |
|
|
2021
Q1 | $66.4M | Buy |
882,624
+32,188
| +4% | +$2.34M | 0.15% | 141 |
|
|
2020
Q4 | $58.1M | Buy |
850,436
+17,610
| +2% | +$1.15M | 0.14% | 140 |
|
|
2020
Q3 | $48.6M | Sell |
832,826
-49,637
| -6% | -$3.09M | 0.13% | 146 |
|
|
2020
Q2 | $57.3M | Buy |
882,463
+10,806
| +1% | +$680K | 0.16% | 126 |
|
|
2020
Q1 | $51.8M | Buy |
871,657
+53,978
| +7% | +$3.6M | 0.16% | 117 |
|
|
2019
Q4 | $60.7M | Sell |
817,679
-49,146
| -6% | -$3.45M | 0.15% | 123 |
|
|
2019
Q3 | $54.7M | Buy |
866,825
+6,414
| +0.7% | +$380K | 0.14% | 134 |
|
|
2019
Q2 | $46.9M | Sell |
860,411
-200,741
| -19% | -$10.8M | 0.1% | 177 |
|
|
2019
Q1 | $57.2M | Sell |
1,061,152
-487,624
| -31% | -$30.1M | 0.12% | 144 |
|
|
2018
Q4 | $101M | Buy |
1,548,776
+380,798
| +33% | +$28.4M | 0.24% | 92 |
|
|
2018
Q3 | $92M | Sell |
1,167,978
-126,966
| -10% | -$9.08M | 0.17% | 124 |
|
|
2018
Q2 | $83.3M | Sell |
1,294,944
-824,716
| -39% | -$54.3M | 0.16% | 125 |
|
|
2018
Q1 | $132M | Sell |
2,119,660
-2,258,023
| -52% | -$162M | 0.26% | 93 |
|
|
2017
Q4 | $317M | Sell |
4,377,683
-605,886
| -12% | -$44.1M | 0.61% | 45 |
|
|
2017
Q3 | $405M | Buy |
+4,983,569
| New | +$394M | 0.74% | 36 |
|
Other funds holding CVS
Aberdeen Group's CVS Position: Q2 2026 in Review
Aberdeen Group increased its CVS Health (CVS) stake by 7.7% in Q2 2026, buying an estimated $11.2M and bringing the position to 1,739,609 shares worth $180M. The position accounts for 0.25% of the portfolio, ranked #65.
Aberdeen Group first reported a position in CVS in Q3 2017 and has held it in 36 quarters since. The position peaked at $405M in Q3 2017. 2,076 funds tracked by Wall St. Rank hold CVS as of Q2 2026.
- Aberdeen Group held 1,739,609 shares of CVS Health worth $180M as of Q2 2026.
- Aberdeen Group bought 125,103 CVS Health shares in Q2 2026, an estimated $11.2M.
- CVS Health made up 0.25% of Aberdeen Group's portfolio in Q2 2026, its #65 holding.
- Aberdeen Group first reported a position in CVS Health in Q3 2017 and has held it in 36 quarters since.
- Aberdeen Group's CVS Health position peaked at $405M in Q3 2017.
- 2,076 funds tracked by Wall St. Rank held CVS Health as of Q2 2026.
Based on Aberdeen Group's 13F filing for Q2 2026, filed 31 Jul 2026.